Metabolix, Inc.  

(Public, NASDAQ:MBLX)   Watch this stock  
Find more results for MBLX
0.942
+0.002 (0.16%)
Apr 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.92 - 0.97
52 week 0.75 - 2.33
Open 0.92
Vol / Avg. 0.00/144,953.00
Mkt cap 32.88M
P/E     -
Div/yield     -
EPS -0.91
Shares 34.89M
Beta 1.24
Inst. own 21%
May 20, 2014
Metabolix, Inc Annual Shareholder Meeting - 9:30AM EDT - Add to calendar
May 5, 2014
Q1 2014 Metabolix, Inc Earnings Release (Estimated) Add to calendar
Mar 27, 2014
Q4 2013 Metabolix, Inc Earnings Conference Call
Mar 27, 2014
Q4 2013 Metabolix, Inc Earnings Release
Mar 11, 2014
Metabolix, Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -848.07% 8.58%
Operating margin -847.02% 8.51%
EBITD margin - 13.76%
Return on average assets -81.68% 5.32%
Return on average equity -92.62% 8.36%
Employees 93 -
CDP Score - -

Address

21 Erie Street
CAMBRIDGE, MA 02139
United States - Map
+1-617-5831700 (Phone)
+1-617-5831768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Metabolix, Inc. is a bioscience company focused on bringing environmentally friendly solutions to the plastics, chemicals and energy industries. The Company has core capabilities in microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. It has focused on a family of biopolymers found in nature called polyhydroxyalkanoates (PHAs). The Company�s biopolymers, marketed under the Mirel and Mvera brands. Its third technology platform, crop-based businesses, which is at an early stage, is a biorefinery system, which uses plant crops to co-produce PHAs that can be recovered as bioplastics or converted to biobased chemicals while also generating bioenergy or biofuels in an integrated biorefinery.

Officers and directors

Joseph H. Shaulson President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Joseph D. Hill Chief Financial Officer, Treasurer
Age: 50
Bio & Compensation  - Reuters
Johan van Walsem Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Lynne H. Brum Vice President - Marketing and Corporate Communications
Age: 49
Bio & Compensation  - Reuters
Robert E. Engle Vice President - Business and Commercial Development, Biopolymers
Age: 50
Bio & Compensation  - Reuters
Max Senechal Vice President - Biobased Chemicals
Age: 49
Bio & Compensation  - Reuters
Oliver P. Peoples Ph.D. Vice President - Research & Development, Chief Scientific Officer, Director
Age: 55
Bio & Compensation  - Reuters
Sarah P. Cecil General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Peter N. Kellogg Independent Director
Age: 58
Bio & Compensation  - Reuters
Celeste B. Mastin Independent Director
Age: 44
Bio & Compensation  - Reuters